Herzliya, Tel Aviv, Israel Pontifax appeared to be the VC, which was created in 2004. The main department of described VC is located in the Herzliya. The fund was located in Asia if to be more exact in Israel.
The important activity for fund was in 2017. The usual things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 7 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Pontifax performs on 4 percentage points less the average number of lead investments. The fund is generally included in 2-6 deals every year. The increased amount of exits for fund were in 2019.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - Israel. The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight 89bio, Dynacure, Check-Cap. Among the most successful fund investment fields, there are Pharmaceutical, Health Care.
This organization was formed by Ran Nussbaum, Tomer Kariv. The overall number of key employees were 10.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Pontifax, startups are often financed by OrbiMed, Ziegler Meditech Equity Partners, Perceptive Advisors. The meaningful sponsors for the fund in investment in the same round are Docor International Management, Quark Venture, Triventures. In the next rounds fund is usually obtained by Yissum Technology Transfer Company of the Hebrew University, Docor International Management, Clal Biotechnology Industries.
Related Funds
Funds with similar focus
Discover 4 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Adcytherix | $35M | 11 Jun 2024 | Amsterdam, Noord-Holland, The Netherlands | ||
ADCendo | $18M | 29 May 2024 | Copenhagen, Capital Region of Denmark, Denmark | ||
LB Pharmaceuticals | $75M | 24 Jan 2024 | New York, New York, United States | ||
AgomAb Therapeutics | $111M | 11 Oct 2023 | Ghent, East Flanders, Belgium | ||
Abcuro | $155M | 17 Aug 2023 | Newton, Massachusetts, United States | ||
ADCendo | $36M | 04 Apr 2023 | Copenhagen, Capital Region of Denmark, Denmark | ||
Amolyt Pharma | $153M | 06 Jan 2023 | Écully, Rhone-Alpes, France | ||
Precirix | $94M | 16 Mar 2022 | City of Brussels, Belgium | ||
Anaveon | $119M | 16 Dec 2021 | Basel-Country, Switzerland |
– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.
– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Adcytherix | $35M | 11 Jun 2024 | Amsterdam, Noord-Holland, The Netherlands | ||
ADCendo | $18M | 29 May 2024 | Copenhagen, Capital Region of Denmark, Denmark | ||
LB Pharmaceuticals | $75M | 24 Jan 2024 | New York, New York, United States | ||
AgomAb Therapeutics | $111M | 11 Oct 2023 | Ghent, East Flanders, Belgium | ||
Abcuro | $155M | 17 Aug 2023 | Newton, Massachusetts, United States | ||
ADCendo | $36M | 04 Apr 2023 | Copenhagen, Capital Region of Denmark, Denmark | ||
Amolyt Pharma | $153M | 06 Jan 2023 | Écully, Rhone-Alpes, France | ||
Precirix | $94M | 16 Mar 2022 | City of Brussels, Belgium | ||
Anaveon | $119M | 16 Dec 2021 | Basel-Country, Switzerland |
